Puma Biotechnology Inc. shares surged 20% in afternoon trade Wednesday, after the company said an advisory committee for the U.S. Food and Drug Administration has voted 12 to 4 in favor of recommending approval for the company’s neratinib treatment for breast cancer. The vote came after a review of the clinical development program for the drug, which aims to prevent recurrence in early-stage breast cancer patients. Puma stock already rallied Tuesday, after the FDA released favorable briefing documents for the advisory committee meeting. The stock has gained 135% in 2017 so far, while the S&P 500 has gained 7%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News